FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Tecfidera was the best launch in the history of MS drug launches: More than 3,500 physicians have prescribed it. About 25% of Tecfidera patients were not on a prior therapy, while about 75% switched from a different disease-modifying MS therapy"



Tecfidera got off to a fast start in terms of the number of physicians who prescribed it and the number of patients who went on the treatment, Tony Kingsley, Biogen's executive vice president of global commercial operations, told IBD. More than 3,500 physicians have prescribed it. About 25% of Tecfidera patients were not on a prior therapy, while about 75% switched from a different disease-modifying MS therapy.


"I think this  said Robert W. Baird & Co. analyst Chris Raymond. "You've got the best of both worlds. It's an oral therapy for a chronic disease, which is an advantage.
Aubagio, have safety-related deterrents.

Tecfidera is the third oral treatment for MS to come to market. Gilenya from Novartis AG (NVS) won approval in 2010 and Aubagio from Sanofi (SNY) got the nod in 2012.

Sometimes physicians may be hesitant to prescribe a drug that just launched, Kingsley says. "But the broad number of physicians writing prescriptions and putting newly diagnosed patients on Tecfidera are positive indicators about the broad acceptance of the product in the market, and that people think it has a very good profile," he said.

Read More At Investor's Business Daily

Labels: , ,



Go to Newer News Go to Older News